

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF THE RECORDING
OF A CHANGE(PCT Rule 92bis.1 and
Administrative Instructions, Section 422)

From the INTERNATIONAL BUREAU

To:

WEBER, Kenneth, A.
Townsend and Townsend and Crew LLP
8th floor
Two Embarcadero Center
San Francisco, CA 94111-3834
ETATS-UNIS D'AMERIQUE

Date of mailing (day/month/year) 27 September 2000 (27.09.00)	
Applicant's or agent's file reference 15280-382-1PC	IMPORTANT NOTIFICATION
International application No. PCT/US99/28107	International filing date (day/month/year) 24 November 1999 (24.11.99)

1. The following indications appeared on record concerning:		
<input checked="" type="checkbox"/> the applicant	<input checked="" type="checkbox"/> the inventor	<input type="checkbox"/> the agent <input type="checkbox"/> the common representative
Name and Address DEAN, Michael National Institutes of Health 9000 Rockville Pike Building 560, Room 21-18 Frederick, MD 21702 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
2. The International Bureau hereby notifies the applicant that the following change has been recorded concerning:		
<input type="checkbox"/> the person	<input type="checkbox"/> the name	<input checked="" type="checkbox"/> the address <input type="checkbox"/> the nationality <input type="checkbox"/> the residence
Name and Address DEAN, Michael National Cancer Institute - FCRDC Building 560 Room 21-19 Frederick, MD 21702 United States of America	State of Nationality US	State of Residence US
	Telephone No.	
	Facsimile No.	
	Teleprinter No.	
3. Further observations, if necessary:		
4. A copy of this notification has been sent to:		
<input checked="" type="checkbox"/> the receiving Office	<input type="checkbox"/> the designated Offices concerned	
<input type="checkbox"/> the International Searching Authority	<input checked="" type="checkbox"/> the elected Offices concerned	
<input checked="" type="checkbox"/> the International Preliminary Examining Authority	<input checked="" type="checkbox"/> other: DEAN, Michael	

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer A. Karkachi
Facsimile No.: (41-22) 740.14.35	Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
United States Patent and Trademark
Office
Box PCT
Washington, D.C. 20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing:

22 June 2000 (22.06.00)

International application No.:

PCT/US99/28107

Applicant's or agent's file reference:

15280-382-1PC

International filing date:

24 November 1999 (24.11.99)

Priority date:

30 November 1998 (30.11.98)

Applicant:

DEAN, Michael et al

1. The designated Office is hereby notified of its election made:



in the demand filed with the International preliminary Examining Authority on:

05 April 2000 (05.04.00)



in a notice effecting later election filed with the International Bureau on:

2. The election ☒ was



was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer:

J. Zahra

Telephone No.: (41-22) 338.83.38

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



9/856927

(43) International Publication Date
22 June 2000 (22.06.2000)

PCT

(10) International Publication Number
WO 00/036101 A3

(51) International Patent Classification⁷: **C12N 15/12**,
C07K 14/705, C12N 5/10, G01N 33/68, C07K 16/18

(74) Agents: **WEBER, Kenneth, A. et al.**; Townsend and
Townsend and Crew LLP, 8th floor, Two Embarcadero
Center, San Francisco, CA 94111-3834 (US).

(21) International Application Number: PCT/US99/28107

(22) International Filing Date:
24 November 1999 (24.11.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/110,473 30 November 1998 (30.11.1998) US

(71) Applicant (for all designated States except US): **THE
GOVERNMENT OF THE UNITED STATES OF
AMERICA**, represented by **THE SECRETARY, DE-
PARTMENT OF HEALTH AND HUMAN SERVICES**
[US/US]; Bethesda, MD 20859 (US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU,
MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

(88) Date of publication of the international search report:
29 August 2002

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(72) Inventors; and

(75) Inventors/Applicants (for US only): **DEAN, Michael**
[US/US]; National Cancer Institute - FCRDC, Building
560, Room 21-19, Frederick, MD 21702 (US). **ALLIK-
METS, Rando** [EE/US]; 5564 Rivendell Place, Frederick,
MD 21703 (US). **BATES, Susan, E.** [US/US]; 5402 Alta
Vista Road, Bethesda, MD 20814 (US). **FOJO, Antonio,**
T. [US/US]; 18 New Mark Esplanade, Rockville, MD
20850 (US).

(54) Title: AN ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE

(57) Abstract: This invention provides for ATP-binding cassette protein which is responsible for cytotoxin resistance. The invention also provides for methods of expressing the protein and assays for identification of inhibitors of the protein.

WO 00/036101 A3

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

15

Applicant's or agent's file reference 15280-3821PC	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/28107	International filing date (day/month/year) 24/11/1999	Priority date (day/month/year) 30/11/1998
International Patent Classification (IPC) or national classification and IPC C12N15/12		
Applicant THE GOVERNMENT OF THE UNITED STATES ... et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☒ Certain observations on the international application

Date of submission of the demand 05/04/2000	Date of completion of this report 08.02.2001
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Claes, B Telephone No. +49 89 2399 8429 

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/28107

I. Basis of the report

1. This report has been drawn on the basis of *(substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments (Rules 70.16 and 70.17).):*

Description, pages:

1-39 as originally filed

Claims, No.:

1-20 as originally filed

Sequence listing part of the description, pages:

1-4, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☒ furnished subsequently to this Authority in computer readable form.
- ☒ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☒ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
- ☐ the claims, Nos.:
- ☐ the drawings, sheets:

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/28107

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 18.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. 18.

2. A meaningful international preliminary examination report cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

☐ the written form has not been furnished or does not comply with the standard.

☐ the computer readable form has not been furnished or does not comply with the standard.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims 1-17,19,20
	No:	Claims

Inventive step (IS)	Yes:	Claims
---------------------	------	--------

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US99/28107

	No:	Claims	1-17,19,20
Industrial applicability (IA)	Yes:	Claims	1-17,19,20
	No:	Claims	

2. Citations and explanations
see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
see separate sheet

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/28107

Re Item V

Reasoned statement with regard to novelty, inventive step or industrial applicability;
citations and explanations supporting such statement

1. **The priority document for the present application was not available at the time of formulating the present written opinion. The findings in this opinion are based on the assumption that the priority is validly claimed for all claimed subject matter.**
2. The following documents are referred to:

D1 = Allkimets et al. (1996), Human molecular genetics, 5(10):1649-1655.
D2 = Doyle et al. (1998), Proc. Am. Assoc. for Cancer Research, 39, abstract 4475
3. The claimed subject matter appears not to have been known in the art. Hence novelty (article 33.2 PCT) can be accepted.

However, evidently cell lines with resistance to mitoxantrone that exhibit multidrug resistance without overexpressing MRP had been known in the art (see description p. 2 lines 5-9). From one such cell line a gene has been cloned by differential display (see D2). Applicant has essentially repeated the teaching of D2 to a further cell line exhibiting the above said features. This resulted in the protein of the present invention.

In view of the fact that further such cell lines had been known in the art and that the art taught the skilled person that he could clone the like genes with a reasonable expectation of success via disclosed identification and isolation routes, the protein as subject of the present application is not considered to involve an inventive step but merely to result from routine experimentation. Consequently, the subject matter of claims 1-20 lacks inventive step under Article 33.2 PCT.

Re Item VIII

Certain observations on the international application

**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US99/28107

1. The wording "specifically binding" in the context of the claims is unclear (article 6 PCT). In view of the fact that "specifically binding" should actually mean that it only binds the said protein and no other protein, it is unclear how it actually should bind another protein (i.e. possibly having more less than 95 % homology).

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference 15280-382-1PC	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 99/ 28107	International filing date (day/month/year) 24/11/1999	(Earliest) Priority Date (day/month/year) 30/11/1998
Applicant THE GOVERNMENT OF THE UNITED STATES et al		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established by this Authority to read as follows:

AN ATP-BINDING CASSETTE PROTEIN RESPONSIBLE FOR CYTOTOXIN RESISTANCE

5. With regard to the **abstract**,

☐ the text is approved as submitted by the applicant.

☒ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

- ☐ None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 99/28107

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 18
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

See FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 18

Present claim 18 relates to a compound defined by reference to a desirable characteristic or property, namely specifically binding to an ATP-binding cassette protein. The claim covers all compounds having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such compounds. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claim also lacks clarity (Article 6 PCT). An attempt is made to define the compound by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to antibodies.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

Box III TEXT OF THE ABSTRACT (Continuation of item 5 of the first sheet)

This invention provides for ATP-binding cassette protein which is responsible for cytotoxin resistance. The invention also provides for methods of expressing the protein and assays for identification of inhibitors of the protein.

INTERNATIONAL SEARCH REPORT

International Application No

US 99/28107

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/12 C07K14/705 C12N5/10 G01N33/68 C07K16/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C07K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ALLIKMETS R ET AL: "Characterization of the human ABC superfamily: isolation and mapping of 21 new genes using the Expressed Sequence Tags Database" HUMAN MOLECULAR GENETICS,GB,OXFORD UNIVERSITY PRESS, SURREY, vol. 5, no. 10, 1996, pages 1649-1655, XP002120400 ISSN: 0964-6906 abstract page 1649, right-hand column, paragraph 4 -page 1650, left-hand column, paragraph 1 page 1650, left-hand column, paragraph 4 -page 1654, right-hand column, paragraph 1; figure 2; table 1 --- -/--	1,2,7-9

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

6 April 2000

Date of mailing of the international search report

19/04/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Montero Lopez, B

INTERNATIONAL SEARCH REPORT

International Application No

US 99/28107

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>JONG SEOK LEE ET AL.: "Reduced drug accumulation and multidrug resistance in human breast cancer cells without associated P-Glycoprotein or MRP overexpression"</p> <p>JOURNAL OF CELLULAR BIOCHEMISTRY, vol. 65, no. 4, 15 June 1997 (1997-06-15), pages 513-526, XP002135021</p> <p>abstract</p> <p>page 514, left-hand column, paragraph 2</p> <p>page 519, left-hand column, paragraph 2</p> <p>-right-hand column, paragraph 1</p> <p>page 522, right-hand column, paragraph 2</p> <p>-page 524, left-hand column, paragraph 1</p> <p>---</p>	1-20
A	<p>DOYLE, L.A. ET AL.: "Cloning and characterization of Breast Cancer Resistance Protein (BCRP), a novel ATP-binding cassette (ABC) transporter that may contribute to the multidrug-resistance phenotype of MCF-7/AdrVp breast cancer cells."</p> <p>PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 39, 28 March 1998 (1998-03-28)</p> <p>- 1 April 1998 (1998-04-01), page 657</p> <p>XP000891682</p> <p>abstract no. #4475</p> <p>---</p>	1-20
A	<p>LAGE H ET AL: "Cloning and characterization of human cDNAs encoding a protein with high homology to rat intestinal development protein OCI-5"</p> <p>GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, GB, ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 188, no. 2, 1 April 1997 (1997-04-01), pages 151-156, XP004059294</p> <p>ISSN: 0378-1119</p> <p>abstract</p> <p>page 151, left-hand column, paragraph 2</p> <p>-page 155, right-hand column, last paragraph; figures 1,2</p> <p>---</p>	1-20
P,X	<p>WO 99 40110 A (UNIVERSITY OF MARYLAND, BALTIMORE) 12 August 1999 (1999-08-12)</p> <p>page 6, line 5 -page 7, line 3</p> <p>page 9, line 9 -page 10, line 12</p> <p>page 11, line 12 -page 10, line 22;</p> <p>examples 9,10,14</p> <p>---</p> <p>-/--</p>	1-5,7,8, 18-20

INTERNATIONAL SEARCH REPORT

International Application No

US 99/28107

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>BRUIN DE M ET AL: "REVERSAL OF RESISTANCE BY GF120918 IN CELL LINES EXPRESSING THE ABC HALF-TRANSPORTER, MXR"</p> <p>CANCER LETTERS, US, NEW YORK, NY, vol. 146, 1999, pages 117-126, XP000878698</p> <p>ISSN: 0304-3835</p> <p>page 117, left-hand column, paragraph 1</p> <p>-page 118, left-hand column, paragraph 1</p> <p>page 118, left-hand column, paragraph 3 - last paragraph</p> <p>page 118, right-hand column, paragraph 2 - paragraph 3</p> <p>page 118, right-hand column, last paragraph -page 119, left-hand column, paragraph 1</p> <p>page 125, left-hand column, last paragraph -right-hand column, paragraph 1</p> <p>---</p>	13, 14, 16, 17
P, X	<p>KEISUKE MIYAKE ET AL.: "Molecular cloning of cDNAs which are highly overexpressed in Mitoxantrone-resistant cells: Demonstration of homology to ABC transport genes"</p> <p>CANCER RESEARCH, vol. 59, no. 1, 1 January 1999 (1999-01-01), pages 8-13, XP002135022</p> <p>MD US</p> <p>abstract</p> <p>page 8, right-hand column, paragraph 2 - paragraph 3</p> <p>page 9, right-hand column, paragraph 2 -page 10, right-hand column, paragraph 2; figure 2</p> <p>page 12, left-hand column, paragraph 2 -right-hand column, paragraph 2</p> <p>---</p>	1, 2, 7-9
P, X	<p>RANDO ALLIKMETS ET AL.: "A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance"</p> <p>CANCER RESEARCH, vol. 58, no. 23, 1 December 1998 (1998-12-01), pages 5337-5339, XP002135023</p> <p>MD US</p> <p>abstract</p> <p>page 5337, right-hand column, paragraph 6 -page 5338, left-hand column, paragraph 1; figure 2</p> <p>page 5338, right-hand column, paragraph 2</p> <p>page 5339, left-hand column, paragraph 1</p> <p>---</p> <p>-/--</p>	1, 2, 7-9

INTERNATIONAL SEARCH REPORT

International Application No

/US 99/28107

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
T	<p>L. AUSTIN DOYLE ET AL.: "A multidrug resistance transporter from human MCF-7 breast cancer cells" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 95, no. 26, 22 December 1998 (1998-12-22), pages 15665-15670, XP002135024 WASHINGTON US abstract page 15666, left-hand column, paragraph 5; figure 2 page 15667, left-hand column, paragraph 2 -page 15670, left-hand column, paragraph 1 ----</p>	
T	<p>WO 98 55614 A (GENETICS INSTITUTE, INC.) 10 December 1998 (1998-12-10) page 10, line 23 -page 11, line 26 page 22, line 28 -page 23, line 9 page 28, line 11 -page 29, line 15 page 37, line 12 -page 38, line 19 page 42, line 14 -page 43, line 14 sequence listing SEQ ID NOs.: 9 and 10 -----</p>	

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

US 99/28107

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
W0 9940110	A	12-08-1999	AU 2761099	A	23-08-1999
W0 9855614	A	10-12-1998	AU 7807298	A	21-12-1998